All In Biotech

Drug Trial Radar · NCT06805305

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 17, 2025

Primary completion

Mar 2030

Study completion Mar 2032

Sponsor

Lead sponsor
Diakonos Oncology CorporationIndustry
Sponsor type
Industry
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: \- Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation

Conditions

  • Glioblastoma (GBM)

Interventions

  • DOC1021Biological

    Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method

  • Tumor resectionProcedure

    SOC brain tumor resection

  • Temodar (Temozolomide)Drug

    SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation

  • SOC cranial radiationRadiation

    60Gy radiation over 6 weeks in 2Gy fractions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (time in months from randomization until death for each participant)Time frame: 5 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Active not recruiting

  • City of Hope

    Duarte, California · Recruiting

  • HOAG

    Newport Beach, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Cooper University Health Care

    Camden, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Atlantic Health

    Summit, New Jersey · Recruiting

  • Lenox Hill Hospital

    New York, New York · Recruiting

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • UTHealth Houston

    Houston, Texas · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.